Incidence of Second Primary Malignancies in Patients with Castration-Resistant Prostate Cancer: An Observational Retrospective Cohort Study in the United States

Table 4

Second-line therapies indicating castration-resistant prostate cancer (N = 2,234).

Therapy	n
Docetaxel	1,697	76.0
Abiraterone acetate	215	9.6
Sipuleucel-T	191	8.5
Mitoxantrone	86	3.8
Enzalutamide	30	1.3
Cabazitaxel	15	0.7